Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
New England Journal of Medicine2010Vol. 363(9), pp. 830–840
Citations Over TimeTop 1% of 2010 papers
Gerd Walz, Klemens Budde, Marwan Mannaa, Jens Nürnberger, Christoph Wanner, Claudia Sommerer, Ulrich Kunzendorf, Bernhard Banas, Walter H. Hörl, Nicholas Obermüller, Wolfgang Arns, Hermann Pavenstädt, Jens Gaedeke, Martin Büchert, Christoph May, Harald Gschaidmeier, Stefan Krämer, Kai‐Uwe Eckardt
Abstract
Within the 2-year study period,as compared with placebo, everolimus slowed the increase in total kidney volume of patients with ADPKD but did not slow the progression of renal impairment [corrected]. (Funded by Novartis; EudraCT number, 2006-001485-16; ClinicalTrials.gov number, NCT00414440.)
Related Papers
- → MicroRNA-21 Aggravates Cyst Growth in a Model of Polycystic Kidney Disease(2015)91 cited
- → HIF-1α drives cyst growth in advanced stages of autosomal dominant polycystic kidney disease(2018)11 cited
- → Nephrectomy in Autosomal Dominant Polycystic Kidney Disease: A Patient with Exceptionally Large, Still Functioning Kidneys(2014)22 cited
- → Impact of Mammalian Target of Rapamycin Inhibition on Autosomal-Dominant Polycystic Kidney Disease(2010)12 cited
- → Absence of mTOR Inhibitor Effect on Hepatic Cyst Growth: A Case Report of a Kidney Transplant Recipient with Autosomal Dominant Polycystic Kidney Disease(2012)3 cited